TABLE 1.
MICs of omadacycline and comparator antimicrobials against 70 rapidly growing mycobacteriaa
| Organism (n) | MIC type | MIC (μg/ml) of: |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OMC (100% inhibition) |
OMC (80% inhibition) |
DOX | MIN | TGC | AMK | FOX | SXT | LZD | CIP | MXF | IPM | CLR | ||
| M. abscessus subsp. abscessus (20) | Range | 0.06–0.5 | 0.015–0.12 | >8 | 4–>8 | ≤0.015–1 | ≤2–>64 | 32–64 | >4/76 | ≤2–32 | ≥4 | 4–16 | 4–>32 | ≤2–>16 |
| 50% | 0.12 | 0.06 | >8 | >8 | 0.12 | 8 | 32 | >4/76 | 16 | ≥4 | 8 | 8 | ≥16 | |
| 90% | 0.25 | 0.12 | >8 | >8 | 0.25 | 16 | 32 | >4/76 | 32 | ≥4 | 16 | 16 | ≥16 | |
| M. abscessus subsp. massiliense (3) | Range | 0.06–0.25 | 0.015 | >8 | 4–>8 | 0.06–0.25 | 8–32 | 32 | >4/76 | ≤2–16 | ≥4 | 2–16 | 8–32 | ≤2 |
| 50% | 0.12 | 0.015 | >8 | >8 | 0.25 | 8 | 32 | 4/76 | 4 | ≥4 | 4 | 16 | ≤2 | |
| M. chelonae (15) | Range | 0.03–0.5 | 0.004–0.25 | >8 | 4–>8 | 0.015–0.5 | ≤2–32 | >64 | 2/38–>4/76 | ≤2–16 | 0.25–>4 | 1–>16 | 8–>32 | ≤2 |
| 50% | 0.12 | 0.12 | >8 | >8 | 0.25 | 16 | >64 | ≥4/76 | 8 | 2 | 2 | ≥32 | ≤2 | |
| 90% | 0.5 | 0.25 | >8 | >8 | 0.5 | 32 | >64 | ≥4/76 | 16 | ≥4 | 8 | ≥32 | ≤2 | |
| M. goodii (2) | Range | 0.06 | 0.03 | ≤0.12 | ≤0.5 | ≤0.015–0.03 | ≤2 | 32–>64 | ≤1/19 | ≤2 | ≤0.12 | ≤0.06 | ≤2–4 | 16–32 |
| M. wolinskyi (1) | Range | 0.5 | 0.12 | 1 | ≤0.5 | 0.03 | ≤2 | 64 | 2/38 | 4 | 1 | 0.25 | 4 | >32 |
| M. immunogenum (7) | Range | 0.03–0.5 | 0.008–0.5 | 1–>8 | ≤0.5–>8 | 0.03–0.5 | 4–16 | >64 | 2/38–>4/76 | 4–32 | 0.5–>4 | 2–16 | 16–32 | ≤2 |
| 50% | 0.25 | 0.06 | >8 | >8 | 0.12 | 8 | >64 | ≥4/76 | 8 | 2 | 8 | 16 | ≤2 | |
| 90% | 0.5 | 0.5 | >8 | >8 | 0.5 | 16 | >64 | ≥4/76 | 32 | ≥4 | 16 | 32 | ≤2 | |
| M. fortuitum group (12) | Range | 0.06–0.25 | 0.015–0.25 | ≤0.12–>8 | ≤0.5–>8 | ≤0.015–0.12 | ≤2 | ≤16–>64 | ≤1/19–2/38 | ≤2–4 | ≤0.12–0.5 | ≤0.06–0.25 | ≤2–8 | ≤2–>8 |
| 50% | 0.12 | 0.06 | 1 | ≤0.5 | 0.03 | ≤2 | 32 | ≤1/19 | ≤2 | 0.25 | 0.12 | ≤2 | ≥8 | |
| 90% | 0.25 | 0.12 | ≥8 | ≥8 | 0.12 | ≤2 | >64 | 2/38 | 4 | 0.5 | 0.25 | 8 | ≥8 | |
| Doxycycline resistantb (5) | Range | 0.06–0.25 | 0.03–0.25 | 4–>8 | 1–>8 | ≤0.015–0.03 | ||||||||
| 50% | 0.12 | 0.12 | >8 | 4 | 0.03 | |||||||||
| 90% | 0.25 | 0.25 | >8 | >8 | 0.03 | |||||||||
| Doxycycline susceptible (7) | Range | 0.12–0.25 | 0.015–0.12 | ≤0.12–1 | ≤0.5 | ≤0.015–0.12 | ||||||||
| 50% | 0.12 | 0.06 | ≤0.12 | ≤0.5 | 0.03 | |||||||||
| 90% | 0.25 | 0.12 | 1 | ≤0.5 | 0.12 | |||||||||
| M. mucogenicum group (10) | Range | 0.12–1 | 0.03–0.5 | ≤0.12–>8 | ≤0.5–>8 | ≤0.015–0.25 | ≤2 | ≤16 | ≤1/19 | ≤2–4 | ≤0.12–2 | 0.25–1 | ≤2 | ≤2 |
| 50% | 0.25 | 0.12 | 0.25 | ≤0.5 | 0.06 | ≤2 | ≤16 | ≤1/19 | ≤2 | 0.5 | 0.25 | ≤2 | ≤2 | |
| 90% | 0.5 | 0.25 | ≥8 | ≥8 | 0.25 | ≤2 | ≤16 | ≤1/19 | ≤2 | 2 | 0.5 | ≤2 | ≤2 | |
| Doxycycline resistantb (4) | Range | 0.12–0.5 | 0.03–0.25 | 4–>8 | 4–>8 | ≤0.015–0.25 | ||||||||
| 50% | 0.12 | 0.03 | >8 | 4 | 0.06 | |||||||||
| Doxycycline susceptible (6) | Range | 0.25–1 | 0.06–0.5 | ≤0.12–0.25 | ≤0.5 | 0.06–0.25 | ||||||||
| 50% | 0.25 | 0.12 | ≤0.12 | ≤0.5 | 0.06 | |||||||||
| 90% | 1 | 0.5 | 0.25 | ≤0.5 | 0.25 | |||||||||
Because of the small number of isolates tested, M. goodii and M. wolinskyi MIC50 and MIC90 and M. abscessus subsp. massiliense MIC90 were not calculated. Tobramycin MICs are not reported for M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, M. fortuitum group, M. mucogenicum group, M. goodii, and M. wolinskyi per CLSI (36). The tobramycin MIC range, MIC50, and MIC90 for M. chelonae were ≤2 μg/ml and for M. immunogenum were >8 μg/ml. n, number of isolates; OMC, omadacycline; DOX, doxycycline; MIN, minocycline; TGC, tigecycline; AMK, amikacin, FOX, cefoxitin; SXT, trimethoprim-sulfamethoxazole; LZD, linezolid; CIP, ciprofloxacin; MXF, moxifloxacin; IPM, imipenem; CLR, clarithromycin.
Doxycycline-resistant isolates include isolates with intermediate and resistant MICs (≥2 μg/ml).